News & Partnering
Learn more about Imvax
For more detail on our progress, behind the scenes at Imvax, or opportunities to collaborate with us to advance the future of immunotherapy, dive in below.
PHILADELPHIA (May 10, 2022) — Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced that Chief Executive Officer John P. Furey will be presenting... Read more
Imvax Presents New Data on Tumor-Derived Immunotherapies in Glioblastoma, Other Solid Tumors at AACR Annual Meeting 2022
– Promising preclinical findings for ovarian and hepatocellular cancers support platform applicability to multiple solid tumor types – – Predictive model of patient response to IGV-001 for... Read more
PHILADELPHIA (March 9, 2022) — Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced two poster presentations at the American Association for Cancer... Read more
– In vitro and in vivo studies indicate anti-tumor activity overcomes IL-6 via Th1 T cells – PHILADELPHIA (November 9, 2021) —Imvax, Inc., a clinical-stage biotechnology company... Read more